Sanofi’s U.S. consumer products subsidiary Chattem Inc. acquired the rights to the Rolaids brand from McNeil-PPC, Inc. — a division of Johnson & Johnson (NYSE: JNJ) — in January of this year and has lived up to its promise to get the product back on store shelves by the end of 2013. J&J pulled Rolaids from the market in December 2010 following the discovery of contamination in the tablets which were made under contract.
J&J reportedly paid $16.6 billion to Pfizer Inc. (NYSE: PFE) to acquire the Rolaids brand in 2006. The terms of the sale to Sanofi was not disclosed.
TV chef Guy Fieri has been hired to market Rolaids and Chattem said it will resurrect one of the most recognizable taglines in advertising history to support the product launch: “How do you spell relief? R-O-L-A-I-D-S.”
Maybe you had to be there.
Shares of Sanofi are up about 0.2% Monday afternoon at $48.08 in a 52-week range of $42.20 to $55.94.
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.